Adalta Capital Management’s AGF US Market Neutral Anti-Beta Fund BTAL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-15,500
Closed -$315K 89
2022
Q3
$315K Buy
+15,500
New +$309K 0.23% 55
2022
Q2
Sell
-17,500
Closed -$321K 101
2022
Q1
$321K Buy
+17,500
New +$322K 0.16% 61
2021
Q1
Sell
-123,007
Closed -$2.35M 98
2020
Q4
$2.35M Buy
123,007
+17,635
+17% +$369K 1.48% 21
2020
Q3
$2.49M Buy
105,372
+20,465
+24% +$490K 1.81% 18
2020
Q2
$2.07M Buy
84,907
+42,357
+100% +$1.05M 1.65% 22
2020
Q1
$1.09M Buy
+42,550
New +$1.01M 0.99% 27

Other funds holding BTAL

Adalta Capital Management's BTAL Position: Q4 2022 in Review

Adalta Capital Management sold out of AGF US Market Neutral Anti-Beta Fund (BTAL) in Q4 2022, closing a stake of 15,500 shares — an estimated $315K sold.

Adalta Capital Management first reported a position in BTAL in Q1 2020 and held it in 6 quarters. The position peaked at $2.49M in Q3 2020. 80 funds tracked by Wall St. Rank hold BTAL as of Q4 2022.

  • Adalta Capital Management reported no remaining AGF US Market Neutral Anti-Beta Fund position as of Q4 2022 after selling out during the quarter.
  • Adalta Capital Management sold 15,500 AGF US Market Neutral Anti-Beta Fund shares in Q4 2022, an estimated $315K.
  • Adalta Capital Management first reported a position in AGF US Market Neutral Anti-Beta Fund in Q1 2020 and held it in 6 quarters.
  • Adalta Capital Management's AGF US Market Neutral Anti-Beta Fund position peaked at $2.49M in Q3 2020.
  • 80 funds tracked by Wall St. Rank held AGF US Market Neutral Anti-Beta Fund as of Q4 2022.

Based on Adalta Capital Management's 13F filing for Q4 2022, filed 21 Feb 2023.